Bioventus Inc.
BVS
$7.44
-$0.20-2.62%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Net Income | 382.86% | -1,590.38% | 96.77% | 81.22% | -425.19% |
| Total Depreciation and Amortization | 1.55% | 165.87% | -246.75% | -6.23% | 11.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 125.32% | -92.23% | 923.83% | -85.04% | 1,096.07% |
| Change in Net Operating Assets | 101.53% | -1,380.12% | -360.26% | -108.26% | 137.56% |
| Cash from Operations | 234.18% | -200.05% | 87.30% | -31.96% | 352.49% |
| Capital Expenditure | 17.31% | -43.90% | -796.88% | 16.88% | 73.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | -65.74% | -103.43% | 37,762.50% | 16.88% | 92.30% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 89.64% | -- | 100.00% | -170.42% |
| Issuance of Common Stock | 778.00% | -86.40% | 99.46% | -9.20% | 244.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.31% | -313.73% | 2,354.45% | -0.53% | 86.06% |
| Cash from Financing | -1,648.36% | 102.21% | -11,938.40% | 104.61% | -84.94% |
| Foreign Exchange rate Adjustments | -53.02% | 120.84% | -542.70% | 211.22% | 22.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.82% | -1,158.71% | -113.47% | 62.44% | 157.85% |